Treatment of hemoglobin (HBF/HBG) related diseases by inhibition of natural antisense transcript to HBF/HBG

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Hemoglobin (HBF/HBG), in particular, by targeting natural antisense polynucleotides of Hemoglobin (HBF/HBG). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of HBF/HBG.

TREATMENT OF INTERFERON-RELATED DEVELOPMENTAL REGULATOR 1 (IFRD1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IFRD1

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Interferon-related developmental regulator 1 (IFRD1), in particular, by targeting natural antisense polynucleotides of Interferon-related developmental regulator 1 (IFRD1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IFRD1. 1. A method of modulating a function of and/or the expression of an Interferon-related developmental regulator 1 (IFRD1) polynucleotide in a biological system comprising: contacting said system with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a natural antisense of an Interferon-related developmental regulator 1 (IFRD1) polynucleotide; thereby modulating a function of and/or the expression of the Interferon-related developmental regulator 1 (IFRD1) polynucleotide.2. A method of modulating a function of and/or the expression of an Interferon-related developmental regulator 1 (IFRD1) polynucleotide in a biological system according to comprising: contacting said biological system with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a polynucleotide comprising 5 to 30 consecutive nucleotides within the natural antisense transcript nucleotides 1 to 740 of SEQ ID NO: 2 or 1 to 418 of SEQ ID NO: 3 or 1 to 540 of SEQ ID NO: 4 or 1 to 546 of SEQ ID NO: 5 or 1 to 429 of SEQ ID NO: 6 or 1 to 429 of SEQ ID NO: 7; thereby modulating a function of and/or the expression of the Interferon-related developmental regulator 1 (IFRD1) polynucleotide.3. A method of modulating a function of and/or the expression of an Interferon-related developmental regulator 1 (IFRD1) polynucleotide in ...

TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Glial cell derived neurotrophic factor (GDNF), in particular, by targeting natural antisense polynucleotides of Glial cell derived neurotrophic factor (GDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of GDNF.

TREATMENT OF 'IQ MOTIF CONTAINING GTPASE ACTIVATING PROTEIN' (IQGAP) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IQGAP

The present invention relates to antisense oligonucleosides that modulate the expression of and/or function of ‘IQ motif containing GTPase activating protein’ (IQGAP), in particular, by targeting natural antisense polynucleotides of ‘IQ motif containing GTPase activating protein’ (IQGAP). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IQGAP. 1. (canceled)2. (canceled)3. (canceled)4. (canceled)5. (canceled)6. (canceled)7. (canceled)8. (canceled)9. (canceled)10. (canceled)11. (canceled)12. (canceled)13. (canceled)14. (canceled)15. (canceled)16. (canceled)17. A synthetic , modified oligonucleotide of 10 to 30 nucleotides in length comprising at least one modification wherein the at least one modification is selected from: at least one modified sugar moiety; at least one modified internucleotide linkage; at least one modified nucleotide , and combinations thereof; wherein , said oligonucleotide is an antisense compound which hybridizes to a natural antisense polynucleotide of an IQ motif containing GTPase activating protein (IQGAP) and upregulates the function and/or expression of an ‘IQ motif containing GTPase activating protein’ (IQGAP) gene in vivo or in vitro as compared to a normal control18. The oligonucleotide of claim 17 , wherein the at least one modification comprises an internucleotide linkage selected from the group consisting of: phosphorothioate claim 17 , alkylphosphonate claim 17 , phosphorodithioate claim 17 , alkylphosphonothioate claim 17 , phosphoramidate claim 17 , carbamate claim 17 , carbonate claim 17 , phosphate triester claim 17 , acetamidate claim 17 , carboxymethyl ester claim 17 , and combinations thereof.19. The oligonucleotide of claim 17 , wherein said oligonucleotide comprises at least one phosphorothioate internucleotide linkage.20. The oligonucleotide of claim 17 , wherein said oligonucleotide comprises a backbone of ...

TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Glial cell derived neurotrophic factor (GDNF), in particular, by targeting natural antisense polynucleotides of Glial cell derived neurotrophic factor (GDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of GDNF.

TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Glial cell derived neurotrophic factor (GDNF), in particular, by targeting natural antisense polynucleotides of Glial cell derived neurotrophic factor (GDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of GDNF. 1. A method of modulating a function of and/or the expression of a Glial cell derived neurotrophic factor (GDNF) polynucleotide in patient cells or tissues in vivo or in vitro comprising:{'figref': {'@idref': 'DRAWINGS', 'FIG. 3'}, 'contacting said cells or tissues with at least one antisense oligonucleotide of about 5 to about 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a polynucleotide comprising about 5 to about 30 consecutive nucleotides within nucleotides 1 to 237 of SEQ ID NO: 2 or nucleotides 1 to 1246 of SEQ ID NO: 3 or nucleotides 1 to 684 of SEQ ID NO: 4 (), or nucleotides 1 to 400 of SEQ ID NO: 42 or nucleotides 1 to 619 of SEQ ID NO: 43 or nucleotides 1 to 813 of SEQ ID NO: 44;'}thereby modulating a function of and/or the expression of the Glial cell derived neurotrophic factor (GDNF) polynucleotide in patient cells or tissues in vivo or in vitro.2. A method of modulating a function of and/or the expression of a Glial cell derived neurotrophic factor (GDNF) polynucleotide in patient cells or tissues in vivo or in vitro comprising:contacting said cells or tissues with at least one antisense oligonucleotide of about 5 to about 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a natural antisense of a Glial cell derived neurotrophic factor (GDNF) polynucleotide;thereby modulating a function of and/or the expression of the Glial cell derived neurotrophic factor ...

TREATMENT OF DISCS LARGE HOMOLOG (DLG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO DLG

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Discs large homolog (DLG), in particular, by targeting natural antisense polynucleotides of Discs large homolog (DLG). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of DLG. 1. A method of modulating a function of and/or the expression of a Discs large homolog (DLG) polynucleotide in a biological system comprising: contacting said system with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a natural antisense of a Discs large homolog (DLG) polynucleotide; thereby modulating a function of and/or the expression of the Discs large homolog (DLG) polynucleotide.2. A method of modulating a function of and/or the expression of a Discs large homolog 1 (DLG1) polynucleotide in a biological system according to comprising: contacting said biological system with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a polynucleotide comprising 5 to 30 consecutive nucleotides within the natural antisense transcript nucleotides 1 to 1706 of SEQ ID NO: 2; thereby modulating a function of and/or the expression of the Discs large homolog 1 (DLG1) polynucleotide.3. A method of modulating a function of and/or the expression of a Discs large homolog (DLG) polynucleotide in patient cells or tissues in vivo or in vitro comprising: contacting said cells or tissues with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said oligonucleotide has at least 50% sequence identity to an antisense oligonucleotide to the Discs large homolog (DLG) polynucleotide; thereby modulating a function of and/or the ...

TREATMENT OF SODIUM CHANNEL, VOLTAGE-GATED, ALPHA SUBUNIT (SCNA) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SCNA

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sodium channel, voltage-gated, alpha subunit (SCNA), in particular, by targeting natural antisense polynucleotides of Sodium channel, voltage-gated, alpha subunit (SCNA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SCNA. 1. A method of modulating a function of and/or the expression of a Sodium channel , voltage-gated , alpha subunit (SCNA) polynucleotide in a biological system comprising: contacting said system with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a natural antisense of a Sodium channel , voltage-gated , alpha subunit (SCNA) polynucleotide; thereby modulating a function of and/or the expression of the Sodium channel , voltage-gated , alpha subunit (SCNA) polynucleotide.2. A method of modulating a function of and/or the expression of a Sodium channel claim 1 , voltage-gated claim 1 , alpha subunit SCN1A polynucleotide in a biological system according to comprising: contacting said claim 1 , biological system with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a polynucleotide comprising 5 to 30 consecutive nucleotides within the natural antisense transcript nucleotides 1 to 1123 of SEQ ID NO: 12 and 1 to 2352 of SEQ ID NO: 13 claim 1 , 1 to 267 of SEQ ID NO: 14 claim 1 , 1 to 1080 of SEQ ID NO: 15 claim 1 , 1 to 173 of SEQ ID NO: 16 claim 1 , 1 to 618 of SEQ ID NO: 17 claim 1 , 1 to 871 of SEQ ID NO: 18 claim 1 , 1 to 304 of SEQ ID NO: 19 claim 1 , 1 to 293 of SEQ ID NO: 20 claim 1 , 1 to 892 of SEQ ID NO: 21 claim 1 , 1 to 260 of SEQ ID NO: 22 claim 1 , 1 to 982 of SEQ ID ...

TREATMENT OF SIRTUIN 1 (SIRT1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SIRTUIN 1

Oligonucleotide compounds modulate expression and/or function of Sirtuin 1 (SIRT1) polynucleotides and encoded products thereof. Methods for treating diseases associated with Sirtuin 1 (SIRT1) comprise administering one or more Oligonucleotide compounds designed to inhibit the SIRT1 natural antisense transcript to patients.

Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Brain derived neurotrophic factor (BDNF), in particular, by targeting natural antisense polynucleotides of Brain derived neurotrophic factor (BDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of BDNF.

TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO BDNF

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Brain derived neurotrophic factor (BDNF), in particular, by targeting natural antisense polynucleotides of Brain derived neurotrophic factor (BDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of BDNF. 1. A method of upregulating a function of and/or the expression of a Brain derived neurotrophic factor (BDNF) polynucleotide in a biological system comprising: contacting said system with at least one antisense oligonucleotide 10 to 30 nucleotides in length wherein said at least one oligonucleotide is at least 90% complementary to and specifically hybridizes to a 10 to 30 nucleotide region of a natural antisense polynucleotide of the BDNF polynucleotide , wherein said natural antisense polynucleotide consists essentially of a sequence selected from the group consisting of nucleotides 1 to 1279 of SEQ ID NO: 3 , 1 to 1478 of SEQ ID NO: 4 , 1 to 1437 of SEQ ID NO: 5 , 1 to 2322 of SEQ ID NO: 6 , 1 to 2036 of SEQ ID NO: 7 , 1 to 2364 of SEQ ID NO: 8 , 1 to 906 of SEQ ID NO: 10 , and 1 to 992 of SEQ ID NO: 11; thereby upregulating the function of and/or the expression of the BDNF polynucleotide , with the proviso that the oligonucleotides having SEQ ID NOS: 50-55 are excluded.2. (canceled)3. (canceled)4. A method of upregulating a function of and/or the expression of a BDNF polynucleotide in patient cells or tissues comprising: contacting said patient cells or tissues with at least one antisense oligonucleotide 10 to 30 nucleotides in length wherein said at least one oligonucleotide is 100% complementary to and specifically hybridizes to a 10 to 30 nucleotide region of a natural antisense polynucleotide of BDNF consisting essentially of a sequence selected from the group consisting of nucleotides 1 to 1279 of SEQ ID NO: 3 , 1 to 1478 of SEQ ID ...

Treatment of 'IQ motif containing GTPase activating protein' (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of IQ motif containing GTPase activating protein (IQGAP), in particular, by targeting natural antisense polynucleotides of IQ motif containing GTPase activating protein (IQGAP). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IQGAP.

Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Alpha-L-Iduronidase (IDUA), in particular, by targeting natural antisense polynucleotides of Alpha-L-Iduronidase (IDUA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IDUA.

TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO BDNF

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Brain derived neurotrophic factor (BDNF), in particular, by targeting natural antisense polynucleotides of Brain derived neurotrophic factor (BDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of BDNF.

TREATMENT OF 'C TERMINUS OF HSP70-INTERACTING PROTEIN' (CHIP) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO CHIP

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of ‘C terminus of HSP70-Interacting Protein’ (CHIP), in particular, by targeting natural antisense polynucleotides of ‘C terminus of HSP70-Interacting Protein’ (CHIP). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of CHIP.

TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Glial cell derived neurotrophic factor (GDNF), in particular, by targeting natural antisense polynucleotides of Glial cell derived neurotrophic factor (GDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of GDNF.

TREATMENT OF FILAGGRIN (FLG) RELATED DISEASES BY MODULATION OF FLG EXPRESSION AND ACTIVITY

The present invention relates to antisense oligonucleotides and/or compounds that modulate the expression of and/or function of Filaggrin (FLG), in particular, by targeting natural antisense polynucleotides of Filaggrin (FLG). The invention also relates to the identification of these antisense oligonucleotides and/or compounds and their use in treating diseases and disorders associated with the expression of FLG.

TREATMENT OF FILAGGRIN (FLG) RELATED DISEASES BY MODULATION OF FLG EXPRESSION AND ACTIVITY

The present invention relates to antisense oligonucleotides and/or compounds that modulate the expression of and/or function of Filaggrin (FLG), in particular, by targeting natural antisense polynucleotides of Filaggrin (FLG). The invention also relates to the identification of these antisense oligonucleotides and/or compounds and their use in treating diseases and disorders associated with the expression of FLG. 1. A method of modulating a function of and/or the expression of a Filaggrin (FLG) polynucleotide in patient cells or tissues in vivo or in vitro comprising:contacting said cells or tissues with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein, said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a polynucleotide comprising 5 to 30 consecutive nucleotides within nucleotides 1 to 4629 of SEQ ID NO: 2; thereby modulating a function of and/or the expression of the Filaggrin (FLG) polynucleotide in patient cells or tissues in vivo or in vitro.2. A method of modulating a function of and/or the expression of a Filaggrin (FLG) polynucleotide in patient cells or tissues in vivo or in vitro comprising:contacting said cells or tissues with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein, said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a natural antisense of a Filaggrin (FLG) polynucleotide; thereby modulating a function of and/or the expression of the Filaggrin (FLG) polynucleotide in patient, cells or tissues in vivo or in vitro.3. A method of modulating a function of and/or the expression of a Filaggrin (FLG) polynucleotide in patient cells or tissues in vivo or in vitro comprising:contacting said cells or tissues with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said oligonucleotide has at least 50% sequence identity to an antisense oligonucleotide to the Filaggrin (FLG) polynucleotide; ...

Treatment of sodium channel, voltage-gated, alpha subunit (SCNA) related diseases by inhibition of natural antisense transcript to SCNA

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sodium channel, voltage-gated, alpha subunit (SCNA), in particular, by targeting natural antisense polynucleotides of Sodium channel, voltage-gated, alpha subunit (SCNA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SCNA.

TREATMENT OF SIRTUIN (SIRT) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A SIRTUIN (SIRT)

The present invention relates to antisense oligonucleotide that modulate the expression of and/or function of a Sirtuin (SIRT), in particular, by targeting natural antisense polynucleotides of a Sirtuin (SIRT). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Sirtuins (SIRT)s. 1. A method of modulating a function of and/or the expression of a Sirtuin (SIRT) polynucleotide in patient cells or tissues in vivo or in vitro comprising: contacting said cells or tissues with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a polynucleotide comprising 5 to 30 consecutive nucleotides within nucleotides 1 to 1028 of SEQ ID NO: 9 or nucleotides 1 to 429 of SEQ ID NO: 10 , or nucleotides 1 to 508 of SEQ ID NO: 11 or nucleotides 1 to 593 of SEQ ID NO: 12 , 1 to 373 of SEQ ID NO: 13 , 1 to 1713 of SEQ ID NO: 14 , 1 to 660 of SEQ ID NO: 15 , 1 to 589 of SEQ ID NO: 16 , 1 to 726 of SEQ ID NO: 17 , 1 to 320 of SEQ ID NO: 18 , 1 to 616 of SEQ ID NO: 19 , 1 to 492 of SEQ ID NO: 20 , 1 to 428 of SEQ ID NO: 21 , 1 to 4041 of SEQ ID NO: 22 or 1 to 705 of SEQ ID NO: 23 or 1 to 2714 of SEQ ID NO: 141 or 1 to 1757 of SEQ ID NO: 142 or 1 to 3647 of SEQ ID NO: 143; thereby modulating a function of and/or the expression of the Sirtuin (SIRT) polynucleotide in patient cells or tissues in vivo or in vitro.2. (canceled)3. (canceled)4. (canceled)5. (canceled)6. (canceled)7. (canceled)8. (canceled)9. (canceled)10. (canceled)11. (canceled)12. (canceled)13. (canceled)14. (canceled)15. (canceled)16. (canceled)17. A synthetic , modified oligonucleotide of 10 to 30 nucleotides in length comprising at least one modification wherein the at least one modification is selected from: at least one modified sugar moiety; at least one modified internucleotide linkage; at ...

Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Discs large homolog (DLG), in particular, by targeting natural antisense polynucleotides of Discs large homolog (DLG). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of DLG.

TREATMENT OF INTERFERON-RELATED DEVELOPMENTAL REGULATOR 1 (IFRD1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IFRD1

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Interferon-related tested developmental regulator 1 (IFRD1), in particular, by targeting natural antisense polynucleotides of interferon-related developmental regulator 1 (IFRD1). The invention also relates to the identification of these antisense oligonucleotides and their use in framing diseases and disorders associated with the expression of IFRD1. 1. A method of modulating a function of and/or the expression of an Interferon-related developmental regulator 1 (IFRD1) polynucleotide in a biological system comprising: contacting said system with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identify to a reverse complement of a natural antisense of an Interferon-related developmental regulator 1 (IFRD1) polynucleotide; thereby modulating a function of and/or the expression of the Interferon-related developmental regulator 1 (IFRD1) polynucleotide.2. A method of modulating a function of and/or the expression of an Interferon-related developmental regulator 1 (IFRD1) polynucleotide in a biological system according to comprising: contacting said biological system with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a polynucleotide comprising 5 to 30 consecutive nucleotides within the natural antisense transcript nucleotides 1 to 740 of SEQ ID NO: 2 or 1 to 418 of SEQ ID NO: 3 or 1 to 540 of SEQ ID NO: 4 or 1 to 546 of SEQ ID NO: 5 or 1 to 429 of SEQ ID NO: 6 or 1 so 429 of SEQ ID NO: 7; thereby modulating a function of and/or the expression of the Interferon-related developmental regulater 1 (IFRD1) polynucleotide.3. A method of modulating a function of and/or the expression of an Interferon-related developmental regulator 1 (IFRD1) ...

Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT)

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Sirtuin (SIRT), in particular, by targeting natural antisense polynucleotides of a Sirtuin (SIRT). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Sirtuins (SIRT)s.

TREATMENT OF ALPHA-L-IDURONIDASE (IDUA) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IDUA

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Alpha-L-Iduronidase (IDUA), in particular, by targeting natural antisense polynucleotides of Alpha-L-Iduronidase (IDUA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IDUA. 1. (canceled)2. (canceled)3. (canceled)4. (canceled)5. (canceled)6. (canceled)7. (canceled)8. (canceled)9. (canceled)10. (canceled)11. (canceled)12. (canceled)13. (canceled)14. (canceled)15. (canceled)16. (canceled)17. (canceled)18. A synthetic , modified oligonucleotide of 10-30 nucleotides in length comprising at least one modification wherein the at least one modification is selected from: at least one modified sugar moiety; at least one modified internucleotide linkage; at least one modified nucleotide , and combinations thereof; wherein said oligonucleotide is an antisense compound which specifically hybridizes to a natural antisense polynucleotide of an Alpha-L-Iduronidase (IDUA) gene and upregulates the function and/or expression of an Alpha-L-Iduronidase (IDUA) gene in vivo or in vitro as compared to a normal control.19. The oligonucleotide according to wherein said oligonucleotide is 12 to 30 nucleotides in length and has at least 90% sequence identity to 12-30 consecutive nucleotides within a premRNA transcript of the IDUA gene.20. The oligonucleotide of claim 18 , wherein the at least one modification comprises an internucleotide linkage selected from the group consisting of: phosphorothioate claim 18 , alkylphosphonate claim 18 , phosphorodithioate claim 18 , alkylphosphonothioate claim 18 , phosphoramidate claim 18 , carbamate claim 18 , carbonate claim 18 , phosphate triester claim 18 , acetamidate claim 18 , carboxymethyl ester claim 18 , and combinations thereof.21. The oligonucleotide of claim 18 , wherein said oligonucleotide comprises at least one ...

Treatment of Sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a Sirtuin (SIRT)

The present invention relates to antisense oligonucleotide that modulate the expression of and/or function of a Sirtuin (SIRT), in particular, by targeting natural antisense polynucleotides of a Sirtuin (SIRT). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Sirtuins (SIRT)s.

Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Brain derived neurotrophic factor (BDNF), in particular, by targeting natural antisense polynucleotides of Brain derived neurotrophic factor (BDNF). The invention also relates to the identification of these antisense oligonecleotides and their use in treating diseases and disorders associated with the expression of BDNF.

Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Alpha-L-Iduronidase (IDUA), in particular, by targeting natural antisense polynucleotides of Alpha-L-Iduronidase (IDUA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IDUA.

TREATMENT OF SIRTUIN (SIRT) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A SIRTUIN (SIRT)

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Sirtuin (SIRT), in particular, by targeting natural antisense polynucleotides of a Sirtuin (SIRT). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Sirtuins (SIRT)s. 1. A method of modulating a function of and/or the expression of a Sirtuin (SIRT) polynucleotide in patient cells or tissues in vivo or in vitro comprising: contacting said cells or tissues with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a polynucleotide comprising 5 to 30 consecutive nucleotides within nucleotides 1 to 1028 of SEQ ID NO: 9 or nucleotides 1 to 429 of SEQ ID NO: 10 , or nucleotides 1 to 508 of SEQ ID NO: 11 or nucleotides 1 to 593 of SEQ ID NO: 12 , 1 to 373 of SEQ ID NO: 13 , 1 to 1713 of SEQ ID NO: 14 , 1 to 660 of SEQ ID NO: 15 , 1 to 589 of SEQ ID NO: 16 , 1 to 726 of SEQ ID NO: 17 , 1 to 320 of SEQ ID NO: 18 , 1 to 616 of SEQ ID NO: 19 , 1 to 492 of SEQ ID NO: 20 , 1 to 428 of SEQ ID NO: 21 , 1 to 4041 of SEQ ID NO: 22 or 1 to 705 of SEQ ID NO: 23 or 1 to 2714 of SEQ ID NO: 141 or 1 to 1757 of SEQ ID NO: 142 or 1 to 3647 of SEQ ID NO: 143; thereby modulating a function of and/or the expression of the Sirtuin (SIRT) polynucleotide in patient cells or tissues in vivo or in vitro.2. A method of modulating a function of and/or the expression of a Sirtuin (SIRT) polynucleotide in patient cells or tissues in vivo or in vitro comprising: contacting said cells or tissues with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a natural antisense of a Sirtuin (SIRT) polynucleotide; thereby modulating a function of ...

Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Discs large homolog (DLG), in particular, by targeting natural antisense polynucleotides of Discs large homolog (DLG). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorder associated with the expression of DLG.

Treatment of filaggrin (FLG) related diseases by modulation of FLG expression and activity

The present invention relates to antisense oligonucleotides and/or compounds that modulate the expression of and/or function of Filaggrin (FLG), in particular, by targeting natural antisense polynucleotides of Filaggrin (FLG). The invention also relates to the identification of these antisense oligonucleotides and/or compounds and their use in treating diseases and disorders associated with the expression of FLG.

Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Brain derived neurotrophic factor (BDNF), in particular, by targeting natural antisense polynucleotides of Brain derived neurotrophic factor (BDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of BDNF.

TREATMENT OF NUCLEAR FACTOR (ERYTHROID-DERIVED 2)-LIKE 2 (NRF2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO NRF2

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Nu-clear factor (erythroid-derived 2)-like 2 (NRF2), in particular, by targeting natural antisense polynucleotides of Nuclear factor (erythroid-derived 2)-like 2 (NRF2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of NRF2. 1. A method of modulating a function of and/or the expression of a Nuclear factor (erythroid-derived 2)-like 2 (NRF2) polynucleotide in patient cells or tissues in vivo or in vitro comprising:{'figref': {'@idref': 'DRAWINGS', 'FIG. 3'}, 'contacting said cells or tissues with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a polynucleotide comprising 5 to 30 consecutive nucleotides within nucleotides 1 to 5808 of SEQ ID NO: 3 (); thereby modulating a function of and/or the expression of the Nuclear factor (erythroid-derived 2)-like 2 (NRF2) polynucleotide in patient cells or tissues in vivo or in vitro.'}2. A method of modulating a function of and/or the expression of a Nuclear factor (erythroid-derived 2)-like 2 (NRF2) polynucleotide in patient cells or tissues in vivo or in vitro comprising:contacting said cells or tissues with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a natural antisense of a Nuclear factor (erythroid-derived 2)-like 2 (NRF2) polynucleotide; thereby modulating a function of and/or the expression of the Nuclear factor (erythroid-derived 2)-like 2 (NRF2) polynucleotide in patient cells or tissues in vivo or in vitro.3. A method of modulating a function of and/or the expression of a Nuclear factor (erythroid-derived 2)-like 2 (NRF2) polynucleotide in ...

Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Nuclear factor (erythroid-derived 2)-like 2 (NRF2), in particular, by targeting natural antisense polynucleotides of Nuclear factor (erythroid-derived 2)-like 2 (NRF2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of NRF2.

Treatment of sodium channel, voltage-gated, alpha subunit (SCNA) related diseases by inhibition of natural antisense transcript to SCNA

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sodium channel, voltage-gated, alpha subunit (SCNA), in particular, by targeting natural antisense polynucleotides of Sodium channel, voltage-gated, alpha subunit (SCNA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SCNA.

TREATMENT OF DELTA-LIKE 1 HOMOLOG (DLK1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO DLK1

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Delta-like (1) homolog (DLK1), in particular, by targeting natural antisense polynucleotides of Delta-like (1) homolog (DLK1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression (DLK1). 1. A method of modulating as function of and/or the expression of a Delta-like 1 homolog (DLK1) polynucleotide in patient cells or tissues in i o or in vitro comprising:{'figref': {'@idref': 'DRAWINGS', 'FIG. 3'}, 'contacting said cells or tissues with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a polynucleotide comprising 5 to 30 consecutive nucleotides within nucleotides 1 to 1347 of SEQ ID NO: 3 (); thereby modulating a function of and/or the expression of the Delta-like homolog (DLK1) polynucleotide in patient cells or tissues in vivo or in vitro.'}2. A method of modulating a function of and/or the expression of a Delta-like 1 homolog (DLK1) polynucleotide in patient cells or tissues in vivo or in vitro comprising:contacting said cells or tissues with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a natural antisense of a Delta-like 1 homolog (DLK1) polynucleotide; thereby modulating a function of and/or the expression of the Delta-like 1 homolog (DLK1) polynucleotide in patient cells or tissues in vivo or in vitro.3. A method of modulating a function of and/or the expression of a Delta-like 1 homolog (DLK1) polynucleotide in patient cells or tissues in vivo or in vitro comprising:contacting said cells or tissues with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said ...

TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Glial cell derived neurotrophic factor (GDNF), in particular, by targeting natural antisense polynucleotides of Glial cell derived neurotrophic factor (GDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of GDNF.

TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO BDNF

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Brain derived neurotrophic factor (BDNP), in particular, by targeting natural antisense polynucleotides of Brain derived neurotrophic factor (BDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of BDNF. 1. (canceled)2. (canceled)3. (canceled)4. (canceled)5. (canceled)6. (canceled)7. (canceled)8. (canceled)9. (canceled)10. (canceled)11. (canceled)12. (canceled)13. (canceled)14. A method of modulating a function of and/or the expression of a Brain derived neurotrophic factor (BDNF) gene in mammalian cells or tissues in vivo or in vitro comprising:contacting said cells or tissues with at least one short interfering RNA (siRNA) oligonucleotide about 5 to about 30 nucleotides in length, said at least one siRNA oligonucleotide being specific for an antisense polynucleotide of a Brain derived neurotrophic factor (BDNF) polynucleotide, wherein said at least one siRNA oligonucleotide has at least about 50% sequence identity to a complementary sequence of at least about five consecutive nucleic acids of the antisense and/or sense nucleic acid molecule of the Brain derived neurotrophic factor (BDNF) polynucleotide; and,modulating a function of and/or the expression of Brain derived neurotrophic factor (BDNF) in mammalian cells or tissues in vivo or in vitro.15. The method of claim 14 , wherein said oligonucleotide has at least 80% sequence identity to a sequence of at least about five consecutive nucleic acids that is complementary to the antisense and/or sense nucleic acid molecule of the Brain derived neurotrophic factor (BDNF) polynucleotide.16. (canceled)17. A synthetic claim 14 , modified oligonucleotide of 10 to 30 nucleotides in length comprising at least one modification wherein the at least one modification is selected from: at least one ...

Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Discs large homolog (DLG), in particular, by targeting natural antisense polynucleotides of Discs large homolog (DLG). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of DLG.

Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Delta-like (1) homolog (DLK1), in particular, by targeting natural antisense polynucleotides of Delta-like (1) homolog (DLK1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of (DLK1).

TREATMENT OF 'IQ MOTIF CONTAINING GTPASE ACTIVATING PROTEIN' (IQGAP) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IQGAP

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of ‘IQ motif containing GTPase activating protein’ (IQGAP), in particular, by targeting natural antisense polynucleotides of ‘IQ motif containing GTPase activating protein’ (IQGAP). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IQGAP.

TREATMENT OF ALPHA-L-IDURONIDASE (IDUA) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IDUA

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Alpha-L-Iduronidase (IDUA), in particular, by targeting natural antisense polynucleotides of Alpha-L-Iduronidase (IDUA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IDUA. 1. A method of modulating a function of and/or the expression of an Alpha-L-Iduronidase (IDUA) polynucleotide in a biological system comprising: contacting said system with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a natural antisense of an Alpha-L-Iduronidase (IDUA) polynucleotide; thereby modulating a function of and/or the expression of the Alpha-L-Iduronidase (IDUA) polynucleotide.2. A method of modulating a function of and/or the expression of an Alpha-L-Iduronidase (IDUA) polynucleotide in a biological system according to comprising: contacting said biological system with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a polynucleotide comprising 5 to 30 consecutive nucleotides within the natural antisense transcript nucleotides 1 to 2695 of SEQ ID NO: 2 or 1 to 2082 of SEQ ID NO: 3 or 1 to 322 of SEQ ID NO: 4 or 1 to 677 of SEQ ID NO: 5 or 1 to 716 of SEQ ID NO: 6 or 1 to 466 of SEQ ID NO: 7 or 1 to 1255 of SEQ ID NO: 8 or 1 to 2739 of SEQ ID NO: 9; thereby modulating a function of and/or the expression of the Alpha-L-Iduronidase (IDUA) polynucleotide.3. A method of modulating a function of and/or the expression of an Alpha-L-Iduronidase (IDUA) polynucleotide in patient cells or tissues in vivo or in vitro comprising: contacting said cells or tissues with at least one antisense oligonucleotide 5 to 30 ...

Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Lipid transport and metabolism gene, in particular, by targeting natural antisense polynucleotides of a Lipid transport and metabolism gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of a Lipid transport and metabolism genes.

Treatment of filaggrin (FLG) related diseases by modulation of FLG expression and activity

The present invention relates to antisense oligonucleotides and/or compounds that modulate the expression of and/or function of Filaggrin (FLG), in particular, by targeting natural antisense polynucleotides of Filaggrin (FLG). The invention also relates to the identification of these antisense oligonucleotides and/or compounds and their use in treating diseases and disorders associated with the expression of FLG.

TREATMENT OF DISCS LARGE HOMOLOG (DLG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO DLG

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Discs large homolog (DLG), in particular, by targeting natural antisense polynucleotides of Discs large homolog (DLG). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorder associated with the expression of DLG. 1. (canceled)2. (canceled)3. (canceled)4. (canceled)5. (canceled)6. (canceled)7. (canceled)8. (canceled)9. (canceled)10. (canceled)11. (canceled)12. (canceled)13. (canceled)14. (canceled)15. (canceled)16. (canceled)17. (canceled)18. A synthetic , modified oligonucleotide of 10 to 30 nucleotides in length comprising at least one modification wherein the at least one modification is selected from: at least one modified sugar moiety; at least one modified , internucleotide linkage; at least one modified nucleotide , and combinations thereof; wherein said oligonucleotide is an antisense compound which specifically hybridizes to a natural antisense polynucleotide of a Discs large homolog 1 (DLG1) gene and upregulates the function and/or expression of a Discs large homolog 1 (DLG1) gene in vivo or in vitro as compared to a normal control.19. (canceled)20. The oligonucleotide of claim 1 , wherein the at least one modification comprises an internucleotide linkage selected from the group consisting of: phosphorothioate claim 1 , alkylphosphonate claim 1 , phosphorodithioate claim 1 , alkylphosphonothioate claim 1 , phosphoramidate claim 1 , carbamate claim 1 , carbonate claim 1 , phosphate triester claim 1 , acetamidate claim 1 , carboxymethyl ester claim 1 , and combinations thereof.21. The oligonucleotide of claim 19 , wherein said oligonucleotide comprises at least one phosphorothioate internucleotide linkage.22. The oligonucleotide of claim 19 , wherein said oligonucleotide comprises a backbone of phosphorothioate internucleotide linkages.23. The oligonucleotide of claim 1 , ...

Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Delta-like (1) homolog (DLK1), in particular, by targeting natural antisense polynucleotides of Delta-like (1) homolog (DLK1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of (DLK1).

Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Nuclear factor (erythroid-derived 2)-like 2 (NRF2), in particular, by targeting natural antisense polynucleotides of Nuclear factor (erythroid-derived 2)-like 2 (NRF2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of NRF2.

Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Alpha-L-Iduronidase (IDUA), in particular, by targeting natural antisense polynucleotides of Alpha-L-Iduronidase (IDUA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IDUA.

Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Delta-like 1 homolog (DLK1), in particular, by targeting natural antisense polynucleotides of Delta-like 1 homolog (DLK1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of DLK1.

TREATMENT OF SIRTUIN 1 (SIRT1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SIRT1

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sirtuin 1 (SIRT1), in particular, by targeting natural antisense polynucleotides of Sirtuin 1 (SIRT1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SIRT 1.

Treatment of ‘C terminus of HSP7O-interacting protein’ (CHIP) related diseases by inhibition of natural antisense transcript to CHIP

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of ‘C terminus of HSP70-Interacting Protein’ (CHIP), in particular, by targeting natural antisense polynucleotides of ‘C terminus of HSP70-Interacting Protein’ (CHIP). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of CHIP.

TREATMENT OF SODIUM CHANNEL, VOLTAGE-GATED, ALPHA SUBUNIT (SCNA) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SCNA

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sodium channel, voltage-gated, alpha subunit (SCNA), in particular, by targeting natural antisense polynucleotides of Sodium channel, voltage-gated, alpha subunit (SCNA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SCNA. 1. A method of upregulating a function of and/or the expression of a Sodium channel , voltage-gated , alpha subunit (SCN1A) gene in mammalian cells or tissues in vivo or in vitro comprising: contacting said cells or tissues with at least one short interfering RNA (siRNA) oligonucleotide 19 to 30 nucleotides in length , said at least one siRNA oligonucleotide being specific for a natural antisense polynucleotide of a Sodium channel , voltage-gated , alpha subunit (SCN1A) polynucleotide of SEQ ID NO: 12 or of SEQ ID NO: 13 , or of SEQ ID NO: 14 , or of SEQ ID NO:15 , or of SEQ ID NO: 16 , or of SEQ ID NO: 17 , or of SEQ ID NO: 18 , or of SEQ ID NO: 19 , or of SEQ ID NO: 20 , or of SEQ ID NO: 21 , or of SEQ ID NO: 22 , or of SEQ ID NO: 23 , or of SEQ ID NO: 24 , or of SEQ ID NO: 25 , or of SEQ ID NO: 26 , or of SEQ ID NO: 27 or of SEQ ID NO: 28; thereby upregulating a function of and/or the expression of the Sodium channel , voltage-gated , type I , alpha subunit (SCN1A) polynucleotide wherein the at least one oligonucleotide comprises at least one oligonucleotide sequences set forth as SEQ ID NOS: 31 , 33 , 37 , 40 to 92.2. A synthetic , modified oligonucleotide of 10 to 30 nucleotides in length comprising at least one modification wherein the at least one modification is selected from: at least one modified sugar moiety; at least one modified internucleotide linkage; at least one modified nucleotide , and combinations thereof; wherein said oligonucleotide is an antisense compound which specifically hybridizes to a ...

TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO BDNF

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Brain derived neurotrophic factor (BDNF), in particular, by targeting natural antisense polynucleotides of Brain derived neurotrophic factor (BDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of BDNF. 1. A method of modulating a function of and/or the expression of a Brain derived neurotrophic factor (BDNF) polynucleotide in a biological system comprising: contacting said system with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a natural antisense of a Brain derived neurotrophic factor (BDNF) polynucleotide; thereby modulating a function of and/or the expression of the Brain derived neurotrophic factor (BDNF) polynucleotide , with the proviso that the oligonucleotides having SEQ ID NOS 50-55 are excluded.2. A method of modulating a function of and/or the expression of a Brain derived neurotrophic factor (BDNF) polynucleotide in a biological system according to comprising: contacting said biological system with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a polynucleotide comprising 5 to 30 consecutive nucleotides within the natural antisense transcript nucleotides 1 to 1279 of SEQ ID NO: 3 or 1 to 1478 of SEQ TD NO: 4 or 1 to 1437 of SEQ ID NO: 5 or 1 to 2322 of SEQ ID NO: 6 or 1 to 2036 of SEQ ID NO: 7 or 1 to 2364 of SEQ ID NO: 8 or 1 to 3136 of SEQ ID NO: 9 or 1 to 906 of SEQ ID NO: 10 or 1 to 992 of SEQ ID NO: 11 claim 1 , with the proviso that the oligonucleotides having SEQ ID NOS 50-55 are excluded. thereby modulating a function of and/or the expression of the Brain derived ...

TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Glial cell derived neurotrophic factor (GDNF), in particular, by targeting natural antisense polynucleotides of Glial cell derived neurotrophic factor (GDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of GDNF. 1. A method of upregulating a function of and/or the expression of a Glial cell derived neurotrophic factor (GDNF) polynucleotide having SEQ ID NO: 1 in patient cells or tissues in vivo or in vitro comprising:contacting said cells or tissues with at least one antisense oligonucleotide of 10 to 30 nucleotides in length that targets and specifically hybridizes to a complementary region of a polynucleotide selected from the group consisting of SEQ ID NOS: 2, 42, 43 and 44;thereby upregulating a function of and/or the expression of the Glial cell derived neurotrophic factor (GDNF) polynucleotide in patient cells or tissues in vivo or in vitro.2. The method of claim 1 , wherein a function of andfor the expression of the Glial cell derived neurotrophic factor (GDNF) is increased in vivo or in vitro with respect to a control.3. The method of claim 1 , wherein the at least one antisense oligonucleotide comprises one or more modifications selected from: at least one modified sugar moiety claim 1 , at least one modified internucleoside linkage claim 1 , at least one modified nucleotide claim 1 , and combinations thereof.4. The method of claim 3 , wherein the one or more modifications comprise at least one modified sugar moiety selected from: a 2′-O-methoxyethyl modified sugar moiety claim 3 , a 2′-methoxy modified sugar moiety claim 3 , a 2′-O-alkyl modified sugar moiety claim 3 , a bicyclic sugar moiety claim 3 , and combinations thereof.5. The method of claim 3 , wherein the one or more modifications comprise at least one modified ...

TREATMENT OF DELTA-LIKE 1 HOMOLOG (DLK1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO DLK1

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Delta-like 1 homolog (DLK1), in particular, by targeting natural antisense polynucleotides of Delta-like 1 homolog (DLK1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of DLK1. 1. A method of testing the modulatory activity at least one modified oligonucleotide of 10 to 30 nucleotides in length that hybridizes to a complementary region of at least one natural antisense polynucleotide of a DLK1 gene as a selected target polynucleotide , comprising:identifying said least one polynucleotide that is antisense to the selected target DLK1 gene polynucleotide;measuring the thermal melting point of a hybrid of a modified antisense oligonucleotide of 10 to 30 nucleotides in length and said antisense polynucleotide under stringent hybridization conditions;identifying at least one modified antisense oligonucleotide of 10 to 30 nucleotides in length that specifically hybridizes to the at least one polynucleotide that is antisense to the selected target DLK1 gene polynucleotide; andmeasuring the modulatory activity of said at least one modified antisense oligonucleotide of 10 to 30 nucleotides in length.2. The method of wherein the modulatory activity tested is a decrease or increase in the mRNA of the DLK1 gene.3. The method of wherein the at least one polynucleotide antisense to the selected target DLK1 gene polynucleotide is a natural antisense polynucleotide of said DLK1 gene.4. The method of wherein the natural antisense polynucleotide has SEQ ID NO: 3.5. The method of claim 1 , wherein the at least one antisense oligonucleotide comprises one or more modifications selected from: at least one modified sugar moiety claim 1 , at least one modified intemucleoside linkage claim 1 , at least one modified nucleotide claim 1 , and combinations thereof.6. ...

Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Alpha-L-Iduronidase (IDUA), in particular, by targeting natural antisense polynucleotides of Alpha-L-Iduronidase (IDUA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IDUA.

TREATMENT OF FILAGGRIN (FLG) RELATED DISEASES BY MODULATION OF FLG EXPRESSION AND ACTIVITY

The present invention relates to antisense oligonucleotides and/or compounds that modulate the expression of and/or function of Filaggrin (FLG), in particular, by targeting natural antisense polynucleotides of Filaggrin (FLG). The invention also relates to the identification of these antisense oligonucleotides and/or compounds and their use in treating diseases and disorders associated with the expression of FLG. 1. A method of modulating a function of and/or the expression of a Filaggrin (FLG) polynucleotide in patient cells or tissues in vivo or in vitro comprising:contacting said cells or tissues with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a polynucleotide comprising 5 to 30 consecutive nucleotides within nucleotides 1 to 4629 of SEQ ID NO: 2; thereby modulating a function of and/or the expression of the Filaggrin (FLG) polynucleotide in patient cells or tissues in vivo or in vitro.2. A method of modulating a function of and/or the expression of a Filaggrin (FLG) polynucleotide in patient cells or tissues in vivo or in vitro comprising:contacting said cells or tissues with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a natural antisense of a Filaggrin (FLG) polynucleotide; thereby modulating a function of and/or the expression of the Filaggrin (FLG) polynucleotide in patient cells or tissues in vivo or in vitro.3. A method of modulating a function of and/or the expression of a Filaggrin (FLG) polynucleotide in patient cells or tissues in vivo or in vitro comprising:contacting said cells or tissues with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said oligonucleotide has at least 50% sequence identity to an antisense oligonucleotide to the Filaggrin (FLG) polynucleotide; ...

TREATMENT OF NUCLEAR FACTOR (ERYTHROID-DERIVED 2)-LIKE 2 (NRF2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO NRF2

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Nuclear factor (erythroid-derived 2)-like 2 (NRF2), in particular, by targeting natural antisense polynucleotides of Nuclear factor (erythroid-derived 2)-like 2 (NRF2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of NRF2. 1. A method of upregulating a function of and/or the expression of a Nuclear factor (erythroid-derived 2)-like 2 (NRF2) gene in mammalian cells or tissues in vivo or in vitro comprising: contacting said cells or tissues with at least one short interfering RNA (siRNA) oligonucleotide 19 to 30 nucleotides in length , said at least one siRNA oligonucleotide being specific for a natural antisense polynucleotide of a Nuclear factor (erythroid-derived 2)-like 2 (NRF2) polynucleotide , wherein said at least one siRNA oligonucleotide upregulates a function of and/or the expression of Nuclear factor (erythroid-derived 2)-like 2 (NRF2) in mammalian cells or tissues in vivo or in vitro.2. The method of claim 1 , wherein said siRNA oligonucleotide targets a non-overlapping region of the natural antisense polynucleotide of the Nuclear factor (erythroid-derived 2)-like 2 (NRF2) polynucleotide.3. A synthetic claim 1 , modified oligonucleotide of 10 to 30 nucleotides in length comprising at least one modification wherein the at least one modification is selected from: at least one modified sugar moiety; at least one modified internucleotide linkage; at least one modified nucleotide claim 1 , and combinations thereof; wherein said oligonucleotide is an antisense compound which specifically hybridizes to a complementary region of a natural antisense polynucleotide of the NRF2 gene and upregulates the function and/or expression of a Nuclear factor (erythroid-derived 2)-like 2 (NRF2) gene in vivo or in vitro as compared to a normal control. ...

TREATMENT OF 'C TERMINUS OF HSP70-INTERACTING PROTEIN' (CHIP) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO CHIP

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of ‘C terminus of HSP70-Interacting Protein’ (CHIP), in particular, by targeting natural antisense polynucleotides of ‘C terminus of HSP70-Interacting Protein’ (CHIP). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of CHIP. 1. A method of modulating a function of and/or the expression of a ‘C terminus of HSP70-Interacting Protein’ (CHIP) polynucleotide in patient cells or tissues in vivo or in vitro comprising:contacting said cells or tissues with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a polynucleotide comprising 5 to 30 consecutive nucleotides within nucleotides 1 to 2074 of SEQ ID NO: 2 and 1 to 1237 of SEQ ID NO: 3; (hereby modulating a function of and/or the expression off the ‘C terminus of HSP70-Interacting Protein ’ (CHIP) polynucleotide in patient cells or tissues in vivo or in vitro.2. A method of modulating a function of and/or the expression of a ‘C terminus of HSP70-Interacting Protein’ (CHIP) polynucleotide in patient cells or tissues in vivo or in vitro comprising:contacting said cells or tissues with at least one antisense oligonucleotide 5 to 30 nucleotides in length, wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a natural antisense of a ‘C terminus of HSP70-Interacting Protein’ (CHIP) polynucleotide; thereby modulating a function of and/or the expression of the ‘C terminus of HSP70-Interacting Protein’ (CHIP) polynucleotide in patient cells or tissues in vivo or in vitro.3. A method of modulating a function of and/or the expression of a ‘C terminus of HSP70-Interacting Protein’ (CHIP) polynucleotide in patient cells or tissues in vivo or ...

TREATMENT OF DISCS LARGE HOMOLOG (DLG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO DLG

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Discs large homolog (DLG), in particular, by targeting natural antisense polynucleotides of Discs large homolog (DLG). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of DLG. 1. A method of identifying and selecting at least one antisense oligonucleotide specific for a target natural antisense transcript of a Discs large homolog 1 (DLG 1) gene wherein the function of and/or expression of said DLG1 gene is modulated by said at least one antisense oligonucleotide comprising: identifying at least one oligonucleotide of 10 to 30 nucleotides which are at least 90% complementary to 10 to 30 nucleotides of a polynucleotide antisense to and having overlapping or non-overlapping sequences with an RNA transcribed from said DLG 1 gene; measuring the thermal melting point of a hybrid of said antisense oligonucleotide and said polynucleotide antisense to said RNA of said DLG-1 gene under stringent hybridization conditions to identify and select at least one antisense oligonucleotide having a high thermal melting point; and measuring the modulation activity of said antisense oligonucleotide identified as having said high thermal melting point; and identifying and selecting at least one antisense oligonucleotide having modulation activity and binding specificity for said target natural antisense transcript.2. The method according to wherein said at least one oligonucleotide has at least 80% sequence identity to a reverse complement of a polynucleotide comprising 10 to 30 consecutive nucleotides within the natural antisense transcript nucleotides 1 to 1706 of SEQ ID NO: 2.3. The method of claim 1 , wherein a function of and/or the expression of the Discs large homolog 1 (DLG 1) is increased in vivo or in vitro with respect to a control.4. The method of claim ...

TREATMENT OF SODIUM CHANNEL, VOLTAGE-GATED, ALPHA SUBUNIT (SCNA) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SCNA

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sodium channel, voltage-gated, alpha subunit (SCNA), in particular, by targeting natural antisense polynucleotides of Sodium channel, voltage-gated, alpha subunit (SCNA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SCNA. 1. A method of modulating a function of and/or the expression of a Sodium channel , voltage-gated , alpha subunit (SCNA) polynucleotide in a biological system comprising:contacting said system with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a natural antisense of a Sodium channel, voltage-gated, alpha subunit (SCNA) polynucleotide; thereby modulating a function of and/or the expression of the Sodium channel, voltage-gated, alpha subunit (SCNA) polynucleotide.2. A method of modulating a function of and/or the expression of a Sodium channel claim 1 , voltage-gated claim 1 , alpha subunit SCN1A polynucleotide in a biological system according to comprising: contacting said biological system with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a polynucleotide comprising 5 to 30 consecutive nucleotides within the natural antisense transcript nucleotides 1 to 1123 of SEQ ID NO: 12 and 1 to 2352 of SEQ ED NO: 13 claim 1 , 1 to 267 of SEQ ED NO: 14 claim 1 , 1 to 1080 of SEQ ID NO:15 claim 1 , 1 to 173 of SEQ ID NO: 16 claim 1 , 1 to 618 of SEQ ID NO: 17 claim 1 , 1 to 871 of SEQ ID NO: 18 claim 1 , 1 to 304 of SEQ ID NO: 19 claim 1 , 1 to 293 of SEQ ID NO: 20 claim 1 , 1 to 892 of SEQ ID NO: 21 claim 1 , 1 to 260 of SEQ ED NO: 22 claim 1 , 1 to 982 of SEQ ED NO: 23 claim 1 , ...

Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf

Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt1

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sirtuin 1 (SIRT1), in particular, by targeting natural antisense polynucleotides of Sirtuin 1 (SIRT1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SIRT 1.

Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1.

La presente invención se refiere a oligonucleótidos antisentido que modulan la expresión de y/o la función de homólogo tipo delta 1 (DLK1) en particular, al dirigir al objetivo polinucleótidos antisentido naturales del homólogo tipo delta (1) (DLK1). La invención también se refiere a la identificación de estos oligonucleótidos antisentido y su uso en el tratamiento de enfermedades y trastornos asociados con la expresión de (DLK1).

Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap

Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)

Treatment of interferon-related developmental regulator 1 (ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Interferon-related developmental regulator 1 (IFRD1), in particular, by targeting natural antisense polynucleotides of Interferon-related developmental regulator 1 (IFRD1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IFRD1.

Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna

Treatment of diseases related to the delta 1 homologue (dlk1) by inhibition of natural antisense transcript to dlk1

Un oligonucleótido antisentido que se dirige a un transcrito antisentido natural de homólogo tipo Delta 1 (DLK1) para uso como compuesto terapéutico, donde el transcrito antisentido natural del DLK1 tiene la secuencia del ácido nucleico tal y como se expone en la SEQ ID NO: 3, y donde el oligonucleótido antisentido aumenta la expresión del homólogo tipo Delta 1 (DLK1).

Treatment of sirtuin1-related diseases (SIRT1) by inhibition of the natural antisense transcript to sirtuin 1

Un oligonucleótido antisentido que se une a un transcrito antisentido natural de Sirtuina 1 (SIRT1) humano para uso como compuesto terapéutico, en donde el transcrito antisentido natural de Sirtuina (SIRT1) es SEQ ID NO: 7, y en donde dicho oligonucleótido antisentido aumenta la expresión de Sirtuina 1 (SIRT1) humana correspondiente a SEQ ID NO: 1.

Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Brain derived neurotrophic factor (BDNF), in particular, by targeting natural antisense polynucleotides of Brain derived neurotrophic factor (BDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of BDNF.

Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Nuclear factor (erythroid-derived 2)-like 2 (NRF2), in particular, by targeting natural antisense polynucleotides of Nuclear factor (erythroid-derived 2)-like 2 (NRF2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of NRF2.

Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Alpha-L-Iduronidase (IDUA), in particular, by targeting natural antisense polynucleotides of Alpha-L-Iduronidase (IDUA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IDUA.

TREATMENT OF BRAIN-DERIVATED NEUROTROPHIC FACTOR- (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO BDNF

Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of 'C terminus of HSP70-Interacting Protein' (CHIP), in particular, by targeting natural antisense polynucleotides of 'C terminus of HSP70-Interacting Protein' (CHIP). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of CHIP.

Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of 'IQ motif containing GTPase activating protein' (IQGAP), in particular, by targeting natural antisense polynucleotides of 'IQ motif containing GTPase activating protein' (IQGAP). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IQGAP.

Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of 'IQ motif containing GTPase activating protein' (IQGAP), in particular, by targeting natural antisense polynucleotides of 'IQ motif containing GTPase activating protein' (IQGAP). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IQGAP.

Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity

Treatment of diseases related to the developmental regulator 1 associated with interferon (ifrd1) by inhibition of the natural antisense transcript to the ifrd1 gene

Un oligonucleótido que se dirige a un transcrito antisentido natural del regulador del desarrollo 1 asociado a interferón (IFRD1) para uso como un compuesto terapéutico, donde el oligonucleótido aumenta la expresión del regulador del desarrollo 1 asociado a interferón (IFRD1); donde el transcrito antisentido natural tiene la secuencia de ácido nucleico tal como se expone en las SEQ ID NO: 2 al 6. An oligonucleotide that targets a natural antisense transcript of the interferon-associated developmental regulator 1 (IFRD1) for use as a therapeutic compound, where the oligonucleotide increases the expression of the interferon-associated developmental regulator 1 (IFRD1); where the natural antisense transcript has the nucleic acid sequence as set forth in SEQ ID NO: 2 to 6.

Treatment of interferon-related developmental regulator 1 (ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1

Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Discs large homolog (DLG), in particular, by targeting natural antisense polynucleotides of Discs large homolog (DLG). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of DLG.

Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of 'C terminus of HSP70-Interacting Protein' (CHIP), in particular, by targeting natural antisense polynucleotides of 'C terminus of HSP70-Interacting Protein' (CHIP). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of CHIP.

Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2

Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Brain derived neurotrophic factor (BDNF), in particular, by targeting natural antisense polynucleotides of Brain derived neurotrophic factor (BDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of BDNF.

Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1

The present invention relates to antisense oligonucleotides that modulate the expression of and / or function of Delta- like (1) homolog (DLK1), in particular, by targeting natural antisense polynucleotides of Delta-like (1) homolog (DLK1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of (DLK1).

Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1

Oligonucleotide compounds modulate expression and/or function of Sirtuin 1(SIRT1) polynucleotides and encoded products thereof. Methods for treating diseases associated with Sirtuin 1(SIRT1) comprise administering one or more Oligonucleotide compounds designed to inhibit the SIRT1 natural antisense transcript to patients.

Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip

Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sirtuin 1 (SIRTl), in particular, by targeting natural antisense polynucleotides of Sirtuin 1 (SIRTl). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SIRT 1.

Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Discs large homolog (DLG), in particular, by targeting natural antisense polynucleotides of Discs large homolog (DLG). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of DLG.

Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua

Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity

The present invention relates to antisense oligonucleotides and/ or compounds that modulate the expression of and/or function of Filaggrin (FLG), in particular, by targeting natural antisense polynucleotides of Filaggrin (FLG). The invention also relates to the identification of these antisense oligonucleotides and/ or compounds and their use in treating diseases and disorders associated with the expression of FLG.

Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Brain derived neurotrophic factor (BDNF), in particular, by targeting natural antisense polynucleotides of Brain derived neurotrophic factor (BDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of BDNF.

Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity

The present invention relates to antisense oligonucleotides and/ or compounds that modulate the expression of and/or function of Filaggrin (FLG), in particular, by targeting natural antisense polynucleotides of Filaggrin (FLG). The invention also relates to the identification of these antisense oligonucleotides and/ or compounds and their use in treating diseases and disorders associated with the expression of FLG.

Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1

The present invention relates to antisense oligonucleotides that modulate the expression of and / or function of Delta- like (1) homolog (DLK1), in particular, by targeting natural antisense polynucleotides of Delta-like (1) homolog (DLK1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of (DLK1).

Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of 'C terminus of HSP70-Interacting Protein' (CHIP), in particular, by targeting natural antisense polynucleotides of 'C terminus of HSP70-Interacting Protein' (CHIP). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of CHIP.

藉由抑制電壓門控鈉離子通道α次單元（ＳＣＮＡ）之天然反義轉錄物治療ＳＣＮＡ相關疾病

本發明係關於反義寡核苷酸，其特別藉由靶向電壓門控鈉離子通道α次單元(SCNA)之天然反義聚核苷酸來調節電壓門控鈉離子通道α次單元(SCNA)之表現及/或功能。本發明亦關於此等反義寡核苷酸之鑑別及其治療與SCNA之表現相關疾病及病症的用途。

معالجة الامراض المتعلقة بقناة الصوديوم , البوابات ذات الجهد الكهربائي , الوحدة الثانوية الفا (scna) بواسطة تثبيط النسخ المضاد للتحسس الطبيعي إلى scna

يختص الاختراع الحالي باوليجونيكلوتيدات المضادة لتحسس antisense oligonucleotides التي تعدل التعبير و / او وظيفة قناة الصوديوم Sodium channel, البوابات ذات الجهد الكهربائي voltage-gated, الوحدة الثانوية الفا alpha subunit (SCNA), علي وجه الخصوص باستهداف اوليجونيكلوتيدات المضادة لتحسيس الطبيعية لقناة الصوديوم, البوابات ذات الجهد الكهربائي, الوحدة الثانوية الفا (SCNA). ايضا يختص الاختراع بتعريف هذه اوليجونيكلوتيدات المضادة لتحسيس واستخدامها في الامراض المعالجة والاضطرابات المرتبطة مع التعبير عن قناة الصوديوم, البوابات ذات الجهد الكهربائي, الوحدة الثانوية الفا (SCNA).

Treatment of ‘IQ motif containing gtpase activating protein’ (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of ‘IQ motif containing GTPase activating protein’ (IQGAP), in particular, by targeting natural antisense polynucleotides of ‘IQ motif containing GTPase activating protein’ (IQGAP). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IQGAP.